CD&R and McKesson Team Up to Acquire Option Care Health for $5.8 Billion
Posted 10/7/2026 3:38AM ET read more Wall Street Journal
CD&R is set to acquire a significant 51% stake in Option Care Health, marking a strategic move in the healthcare sector. In a noteworthy partnership, McKesson, a major player in healthcare services, will invest approximately $1.4 billion to secure a minority interest of 49%. This collaboration underscores the growing trend of consolidation in the healthcare industry as companies aim to enhance their service offerings and strengthen their market positions. As these developments unfold, it will be interesting to observe the implications for Option Care Health and the broader healthcare landscape.
CD&R and McKesson to Acquire At-Home Infusion Therapy Provider for $5.8 Billion
In a significant move within the healthcare sector, Clayton, Dubilier & Rice (CD&R) is poised to acquire a 51% majority stake in Option Care Health, a leading provider of at-home infusion therapy services. McKesson Corporation, a prominent player in healthcare services, will also join this venture by investing approximately $1.4 billion to secure a minority interest of about 49%. This strategic partnership was announced on Tuesday, signaling a notable trend of consolidation in the healthcare industry.
Implications of the Acquisition
The acquisition reflects the increasing demand for healthcare services that prioritize patient convenience and care in home settings. By joining forces, CD&R and McKesson are set to enhance Option Care Health’s service offerings, which cater to an expanding market of patients requiring complex infusions in the comfort of their own homes.
CD&R’s Majority Interest
Holding a majority interest of approximately 51%, CD&R is positioned to steer the direction of Option Care Health and implement strategic initiatives aimed at growth and innovation. This investment marks a pivotal moment for CD&R as they continue to expand their portfolio in the healthcare sector, focusing on companies that align with the evolving needs of patients and healthcare providers.
McKesson’s Strategic Investment
McKesson’s investment of around $1.4 billion for a 49% stake emphasizes its commitment to enhancing healthcare delivery systems. As a well-established entity in the distribution of pharmaceuticals and medical supplies, McKesson’s involvement will likely bolster Option Care Health’s operational capabilities, ensuring streamlined processes and improved access to essential therapies.
Conclusion
As CD&R and McKesson embark on this acquisition, the implications for Option Care Health and the broader healthcare landscape are significant. This partnership not only underscores a shift towards more integrated healthcare solutions but also highlights the ongoing trend of consolidation as companies seek to improve their market positions. Observers will be keen to watch how this acquisition shapes the future of at-home infusion therapy and the impact it has on patient care.
Read more via Wall Street Journal
Leave a comment